ARTICLES BY RONALD A. RADER

  • Biosimilars Pipeline Shows Remarkable, Sustained Growth
    Biosimilars Pipeline Shows Remarkable, Sustained Growth

    The biosimilars pipeline is progressing rapidly and continues to grow, with more products and more organizations involved. This article reviews the current biosimilars development pipeline and progress. 

  • Top Trends In The Biopharmaceutical Industry And Bioprocessing For 2019
    Top Trends In The Biopharmaceutical Industry And Bioprocessing For 2019

    This article presents trends and findings from a survey and study of 222 responsible individuals at biopharmaceutical manufacturers and CMOs in 22 countries, as well as over 130 direct suppliers of materials, services, and equipment to this industry.

  • New Microbiological Methods In Bioprocessing
    New Microbiological Methods In Bioprocessing

    Testing for evidence of microbial contamination in bioprocessing has a long history — and can be expensive, slow, and burdensome. So suppliers, testing facilities, and regulators have been seeking improvements.

  • Overcoming The Manufacturing Hurdles Of Cell & Gene Therapy
    Overcoming The Manufacturing Hurdles Of Cell & Gene Therapy

    A number of innovative cellular and gene therapies are in development, and R&D and investments in these fields are rapidly growing. Although the number of approvals and markets remain very small — negligible by the standards of the mainstream (bio)pharmaceutical industry — this is likely to change as the first clinical trials are successfully concluded.

  • Biosimilars Pipeline Analysis: Many Products, More Competition Coming
    Biosimilars Pipeline Analysis: Many Products, More Competition Coming

    Our discussion of biosimilars in this article will center on developed-market GMP biosimilars. In the European market alone, biosimilars already are a multibillion-dollar business, and one that is rapidly growing.

Ronald A. Rader

Ronald A. Rader

Ronald A. Rader, senior director of technical research at BioPlan Associates, Inc., has 30+ years of experience as a biotechnology, pharmaceutical, and chemical information specialist/analyst. He was editor/publisher of the Antiviral Agents Bulletin, Federal Bio-Technology Transfer Directory, and BIOPHARMA: Biopharmaceutical Products in the U.S. Market.